Related Experiment Video
Updated: Dec 4, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.2K
Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in the Inpatient Setting
1University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA.
Journal of Pharmacy Practice
|October 23, 2020
Summary
Dipeptidyl peptidase-IV (DPP-IV) inhibitors effectively manage blood glucose in hospitalized patients with type 2 diabetes mellitus (T2DM). This study found DPP-IV inhibitor use associated with achieving target blood glucose levels in real-world inpatient settings.
Area of Science:
- Endocrinology
- Pharmacology
- Internal Medicine
Background:
- The American Diabetes Association suggests specific antihyperglycemic management for hospitalized type 2 diabetes mellitus (T2DM) patients.
- Limited data exists on the real-world effectiveness of dipeptidyl peptidase-IV (DPP-IV) inhibitors in hospitalized T2DM patients.
Purpose of the Study:
- To evaluate the efficacy of DPP-IV inhibitor therapy in hospitalized patients diagnosed with T2DM.
Main Methods:
- Adult T2DM patients receiving at least one dose of DPP-IV inhibitors during hospitalization were included.
- Primary outcome: mean daily blood glucose (BG). Secondary outcomes: BG control, hospital length of stay (LOS), and hypoglycemia incidence across different DPP-IV inhibitor regimens.
Main Results:
- Mean daily BG was 158.7 mg/dL across 192 patients.
- Significant differences in mean daily BG were observed between monotherapy, combination with oral agents, and combination with insulin groups (P < 0.001).
- Higher hypoglycemia incidence was noted in the DPP-IV inhibitor plus insulin group (16.3%, P = 0.008), with no significant difference in hospital LOS.
Conclusions:
- Inpatient DPP-IV inhibitor use correlated with achieving target mean daily BG levels.
- Consideration of DPP-IV inhibitors is warranted for hospitalized T2DM patients requiring glycemic control.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
419
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
419
01:24Glucagon-like Receptor Agonists
661
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
661
01:16Insulin: Dosing Regimen and Adverse Effects
513
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
513
01:06Oral Hypoglycemic Agents: Glinides
459
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
459
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
175
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
175
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
117
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
117